In the subgroup of ALK-negative ALCL, CCNA2 and CHEK1 ≥ median were associated with better 3-year PFS (71.4% for CCNA2< median and 100% for CCNA2 ≥ median [p = 0.02] and 75% for CHEK1< median and 100% for CHEK1 ≥ median [p = 0.001]). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.